Tumor glycolysis, an essential sweet tooth of tumor cells

Seminars in Cancer Biology, Journal Year: 2022, Volume and Issue: 86, P. 1216 - 1230

Published: Oct. 28, 2022

Language: Английский

---

Targeting the tumor microenvironment: Potential strategy for cancer therapeutics

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, Journal Year: 2023, Volume and Issue: 1869(6), P. 166746 - 166746

Published: May 7, 2023

Cellular and stromal components including tumor cells, immune mesenchymal cancer-linked fibroblasts, extracellular matrix, constituent microenvironment (TME). TME plays a crucial role in reprogramming initiation, uncontrolled proliferation, invasion metastasis as well response to therapeutic modalities. In recent years targeting the has developed potential strategy for treatment of cancer because its life-threatening functions restricting development modulating responses standard-of-care medicines. Cold atmospheric plasma, oncolytic viral therapy, bacterial nano-vaccine, repurposed pharmaceuticals with combination antiangiogenic drugs, immunotherapies are among most effective therapies directed by that have either been clinically authorized or currently being studied. This article discusses above-mentioned light TME. We also cover problems related TME-targeted therapies, future insights practical uses this rapidly growing field.

Language: Английский

---

Cellular interactions in tumor microenvironment during breast cancer progression: new frontiers and implications for novel therapeutics

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: March 12, 2024

The breast cancer tumor microenvironment (TME) is dynamic, with various immune and non-immune cells interacting to regulate progression anti-tumor immunity. It now evident that the within TME significantly contribute resistance conventional newly developed therapies. Both in play critical roles onset, uncontrolled proliferation, metastasis, evasion, Consequently, molecular cellular components of have emerged as promising therapeutic targets for developing novel treatments. primarily comprises cells, stromal vasculature, infiltrating cells. Currently, numerous clinical trials targeting specific are underway. However, complexity its impact on evasion immunity necessitate further research develop improved multifaceted nature arises from their phenotypic functional plasticity, which endows them both pro during progression. In this review, we discuss current understanding recent advances anti-tumoral functions implications safe effective therapies control progress.

Language: Английский

---

Glucose transporter 4: Insulin response mastermind, glycolysis catalyst and treatment direction for cancer progression

Cancer Letters, Journal Year: 2023, Volume and Issue: 563, P. 216179 - 216179

Published: April 14, 2023

Language: Английский

---

Molecular Mechanisms of Western Diet-Induced Obesity and Obesity-Related Carcinogenesis—A Narrative Review

Metabolites, Journal Year: 2023, Volume and Issue: 13(5), P. 675 - 675

Published: May 21, 2023

The present study aims to provide a narrative review of the molecular mechanisms Western diet-induced obesity and obesity-related carcinogenesis. A literature search Cochrane Library, Embase Pubmed databases, Google Scholar grey was conducted. Most that induce are also involved in twelve Hallmarks Cancer, with fundamental process being consumption highly processed, energy-dense diet deposition fat white adipose tissue liver. generation crown-like structures, macrophages surrounding senescent or necrotic adipocytes hepatocytes, leads perpetual state chronic inflammation, oxidative stress, hyperinsulinaemia, aromatase activity, activation oncogenic pathways loss normal homeostasis. Metabolic reprogramming, epithelial mesenchymal transition, HIF-1α signalling, angiogenesis host immune-surveillance particularly important. Obesity-associated carcinogenesis is closely related metabolic syndrome, hypoxia, visceral dysfunction, oestrogen synthesis detrimental cytokine, adipokine exosomal miRNA release. This important pathogenesis oestrogen-sensitive cancers, including breast, endometrial, ovarian thyroid cancer, but ‘non-hormonal’ obesity-associated cancers such as cardio-oesophageal, colorectal, renal, pancreatic, gallbladder hepatocellular adenocarcinoma. Effective weight interventions may improve future incidence overall cancer.

Language: Английский

---

Hypoxia-inducible factor in breast cancer: role and target for breast cancer treatment

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: May 10, 2024

Globally, breast cancer stands as the most prevalent form of among women. The tumor microenvironment often exhibits hypoxia. Hypoxia-inducible factor 1-alpha, a transcription factor, is found to be overexpressed and activated in cancer, playing pivotal role anoxic by mediating series reactions. 1-alpha involved regulating downstream pathways target genes, which are crucial hypoxic conditions, including glycolysis, angiogenesis, metastasis. These processes significantly contribute progression managing cancer-related activities linked invasion, metastasis, immune evasion, drug resistance, resulting poor prognosis for patients. Consequently, there significant interest potential therapy. Presently, research on drugs targeting predominantly preclinical phase, highlighting need an in-depth understanding HIF-1α its regulatory pathway. It anticipated that future will see introduction effective inhibitors into clinical trials, offering new hope Therefore, this review focuses structure function HIF-1α, advancing strategies combat HIF-1α-dependent underlining therapeutic potential.

Language: Английский

---

Transcriptional regulation and post-translational modifications in the glycolytic pathway for targeted cancer therapy

Acta Pharmacologica Sinica, Journal Year: 2024, Volume and Issue: 45(8), P. 1533 - 1555

Published: April 15, 2024

Language: Английский

---

The Impact of Metabolic Rewiring in Glioblastoma: The Immune Landscape and Therapeutic Strategies

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(2), P. 669 - 669

Published: Jan. 14, 2025

Glioblastoma (GBM) is an aggressive brain tumor characterized by extensive metabolic reprogramming that drives growth and therapeutic resistance. Key pathways, including glycolysis, lactate production, lipid metabolism, are upregulated to sustain survival in the hypoxic nutrient-deprived microenvironment (TME), while glutamine tryptophan metabolism further contribute phenotype of GBM. These alterations impair immune cell function, leading exhaustion stress CD8+ CD4+ T cells favoring immunosuppressive populations such as regulatory (Tregs) M2-like macrophages. Recent studies emphasize role slow-cycling GBM (SCCs), lipid-laden macrophages, tumor-associated astrocytes (TAAs) reshaping GBM’s landscape reinforcing evasion. Genetic mutations, Isocitrate Dehydrogenase (IDH) Epidermal Growth Factor Receptor (EGFR) amplification, Phosphotase Tensin Homolog (PTEN) loss, drive offer potential targets for therapy. Understanding relationship between suppression critical overcoming This review focuses on rewiring GBM, its impact microenvironment, combining targeting with immunotherapy improve clinical outcomes patients.

Language: Английский

---

Evaluation of hypoxia-inducible factor-1 and 2 alpha inhibitory compounds in the oral cavity and pharyngeal cancer

Biomedicine & Pharmacotherapy, Journal Year: 2025, Volume and Issue: 186, P. 118024 - 118024

Published: April 3, 2025

Language: Английский

---

A Novel Radiotherapeutic Approach to Treat Bulky Metastases Even From Cutaneous Squamous Cell Carcinoma: Its Rationale and a Look at the Reliability of the Linear-Quadratic Model to Explain Its Radiobiological Effects

Frontiers in Oncology, Journal Year: 2022, Volume and Issue: 12

Published: Feb. 23, 2022

Metastatic cutaneous squamous cell carcinoma (cSCC) is a very rare condition. The lack of definition an oligometastatic subgroup means that there no consensus for its treatment, unlike the mucosal head and neck counterpart. Like latter, form able to develop bulky tumor masses. When this happens, classic care approach just palliative intent due likely unfavorable benefit-risk balance typical aggressive treatments. Here we proposed novel radiotherapy (RT) technique treat metastases from cSCC in context overall limited burden tried explain clinical outcome by currently available mathematical radiobiological ad hoc developed models.We treated case facial with three metastases: two them stereotactic RT other lattice supported metabolic imaging (18F-FDG PET) excessively large dimensions. For latter lesion, compared four treatment plans different techniques order define best terms normal tissue complication probability (NTCP) control (TCP). Moreover, model could fit better characteristics heterogeneity metastasis which, indeed, segmentation normoxic, hypoxic, necrotic subvolumes might have been assumed.We observed complete response all disease sites; actually regressed more rapidly than RT. NTCP predictions were good but even significantly plan. Neither TCP nor models be totally adequate reported outcome. This finding support key role host immune system.PET-guided safe effective lesions cSCC. There some need complex are take into account any system's possible mechanisms radiation relevant points enhance it.

Language: Английский

---